Evaluation of the Efficacy and Safety of LNZ101 and LNZ100 for the Presbyopia

Exclusion Criteria

• •1. Be a female of childbearing potential who is currently pregnant, nursing, or planning a pregnancy;
• •2. Have known contraindications or sensitivity to the use of any of the study medications or their components;
• •3. Have an active ocular infection at Visit 1 or at Visit 2 (bacterial, viral, or fungal), positive history of an ocular herpetic infection, preauricular lymphadenopathy, or ongoing, active ocular inflammation (e.g., moderate to severe blepharitis, allergic conjunctivitis, peripheral ulcerative keratitis, scleritis, uveitis) in either eye;
• •4. Have moderate or severe dry eye at Visit 1, assessed by corneal fluorescein staining;
• •5. Have clinically significant abnormal lens findings (e.g., cataract) including early lens changes and/or any evidence of a media opacity during dilated slitlamp biomicroscopy and fundus exam documented within 3 months of Visit 1 or at Visit 1;